Advanced search
Add to list

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease

(2009) INFLAMMATORY BOWEL DISEASES. 15(9). p.1295-1301
Author
Organization
Abstract
Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH oil the long-term outcome of IFX treatment in CID is still debated. Methods: We studied MH during long-term treatment with IFX in 214 CID patients. A total of 193 patients (85.5%) responded to induction therapy and 31 patients (14.5%) were primary nonresponders. They underwent lower gastrointestinal (GI) endoscopy within a median of 0.7 months (interquartile range [IQR] 0.1-6.9) prior to first IFX and after a median of 6.7 months (IQR 1.4-24.6) after start of IFX and were further analyzed. The relationship between the outcome of IFX treatment long-term and MH was studied. Results: MH was observed in 67.8% of the 183 initial responders (n = 124), with 83 patients having complete healing (45.4%) and 41 having partial healing (22.4%). Scheduled IFX treatment from the start resulted in MH more frequently (76.9% MH rate) than episodic treatment (61.0% MH rate; P = 0.0222, odds ratio [OR] 2.14, 95% confidence interval [CI] 1.11-4.12). Concomitant treatment with corticosteroids (CS) had a negative impact on MH (37.9% in patients with CS versus 63.2% in patients without CS; P = 0.021, OR 0.36, 95% CI 0.16-0.80). MH was associated with a significantly lower need for major abdominal surgery (MAS) during long-term follow-up (14.1% of patients with MH needed MAS versus 38.4% of patients Without MH: P < 0.0001). Conclusions: MH induced by long-term maintenance IFX treatment is associated with an improved long-term outcome of the I disease especially with a lower need for major abdominal surgeries.
Keywords
INFLAMMATORY-BOWEL-DISEASE, RANDOMIZED-TRIAL, AZATHIOPRINE, EVOLUTION, BEHAVIOR, Crohn's disease, infliximab, mucosal healing, changing disease course, long-term endoscopic outcome

Citation

Please use this url to cite or link to this publication:

MLA
Schnitzler, F., et al. “Mucosal Healing Predicts Long-Term Outcome of Maintenance Therapy with Infliximab in Crohn’s Disease.” INFLAMMATORY BOWEL DISEASES, vol. 15, no. 9, 2009, pp. 1295–301.
APA
Schnitzler, F., Fidder, H., Ferrante, M., Noman, M., Arijs, I., Van Assche, G., … Rutgeerts, P. (2009). Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. INFLAMMATORY BOWEL DISEASES, 15(9), 1295–1301.
Chicago author-date
Schnitzler, F, H Fidder, M Ferrante, M Noman, I Arijs, G Van Assche, I Hoffman, Kristel Van Steen, S Vermeire, and P Rutgeerts. 2009. “Mucosal Healing Predicts Long-Term Outcome of Maintenance Therapy with Infliximab in Crohn’s Disease.” INFLAMMATORY BOWEL DISEASES 15 (9): 1295–1301.
Chicago author-date (all authors)
Schnitzler, F, H Fidder, M Ferrante, M Noman, I Arijs, G Van Assche, I Hoffman, Kristel Van Steen, S Vermeire, and P Rutgeerts. 2009. “Mucosal Healing Predicts Long-Term Outcome of Maintenance Therapy with Infliximab in Crohn’s Disease.” INFLAMMATORY BOWEL DISEASES 15 (9): 1295–1301.
Vancouver
1.
Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease. INFLAMMATORY BOWEL DISEASES. 2009;15(9):1295–301.
IEEE
[1]
F. Schnitzler et al., “Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn’s disease,” INFLAMMATORY BOWEL DISEASES, vol. 15, no. 9, pp. 1295–1301, 2009.
@article{5907086,
  abstract     = {Background: Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH oil the long-term outcome of IFX treatment in CID is still debated. 
Methods: We studied MH during long-term treatment with IFX in 214 CID patients. A total of 193 patients (85.5%) responded to induction therapy and 31 patients (14.5%) were primary nonresponders. They underwent lower gastrointestinal (GI) endoscopy within a median of 0.7 months (interquartile range [IQR] 0.1-6.9) prior to first IFX and after a median of 6.7 months (IQR 1.4-24.6) after start of IFX and were further analyzed. The relationship between the outcome of IFX treatment long-term and MH was studied. 
Results: MH was observed in 67.8% of the 183 initial responders (n = 124), with 83 patients having complete healing (45.4%) and 41 having partial healing (22.4%). Scheduled IFX treatment from the start resulted in MH more frequently (76.9% MH rate) than episodic treatment (61.0% MH rate; P = 0.0222, odds ratio [OR] 2.14, 95% confidence interval [CI] 1.11-4.12). Concomitant treatment with corticosteroids (CS) had a negative impact on MH (37.9% in patients with CS versus 63.2% in patients without CS; P = 0.021, OR 0.36, 95% CI 0.16-0.80). MH was associated with a significantly lower need for major abdominal surgery (MAS) during long-term follow-up (14.1% of patients with MH needed MAS versus 38.4% of patients Without MH: P < 0.0001). 
Conclusions: MH induced by long-term maintenance IFX treatment is associated with an improved long-term outcome of the I disease especially with a lower need for major abdominal surgeries.},
  author       = {Schnitzler, F and Fidder, H and Ferrante, M and Noman, M and Arijs, I and Van Assche, G and Hoffman, I and Van Steen, Kristel and Vermeire, S and Rutgeerts, P},
  issn         = {1078-0998},
  journal      = {INFLAMMATORY BOWEL DISEASES},
  keywords     = {INFLAMMATORY-BOWEL-DISEASE,RANDOMIZED-TRIAL,AZATHIOPRINE,EVOLUTION,BEHAVIOR,Crohn's disease,infliximab,mucosal healing,changing disease course,long-term endoscopic outcome},
  language     = {eng},
  number       = {9},
  pages        = {1295--1301},
  title        = {Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease},
  url          = {http://dx.doi.org/10.1002/ibd.20927},
  volume       = {15},
  year         = {2009},
}

Altmetric
View in Altmetric
Web of Science
Times cited: